Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in HFrEF and HFmrEF
NCT05778084Phase 4Unknown
- Sponsor
- Alexandria University
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), sponsored by Alexandria University. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mildly reduced ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT05778084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778084.